Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment

NCT02244021 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT02244021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
October 31, 2017
Enrollment
13 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory hodgkin's lymphoma